Artificial Intelligence

EvolutionaryScale

Medium2/4 relationships sourcedProfile verified Aug 14, 2026
OverviewSourcesM&A fitRelationship mapStoryMilestones

30-Second Executive Brief

Executive Assessment

EvolutionaryScale functions as a regional institution within Artificial Intelligence, backed by 25% sourcing coverage, with a stable competitive position.

  • Maintains 4 mapped relationships across the graph
  • 25% sourcing coverage across sourced relationships
  • Tracked as regional institution within the Artificial Intelligence category

Executive Snapshot

Strategic Role
Regional Institution
Sourcing Coverage
25%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Moderate
Strategic Momentum
Insufficient Data

Coverage

Mapped Relationships
4
Technology Domains
4

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

Continued development of ESM-family protein language models as a foundation layer for the broader AI protein design ecosystemPotential for downstream commercial products built on top of its open-weight research releases

Top Risks

Horizontal foundation-model strategy requires broad ecosystem adoption to monetize versus applied competitors' direct pharma revenueOpen-weight release strategy could commoditize its own core technology advantage

Critical Dependencies

Meta (Was developed by)
Continue to Dependency Graph ↓

A protein-design foundation model company founded by former Meta AI researchers, positioned as a horizontal, OpenAI-for-proteins platform rather than an applied biologics or optimization tool. EvolutionaryScale raised $142 million in a single seed round in June 2024 -- by far the largest seed financing on record in synthetic biology -- and released the open weights and code for ESM3, its flagship protein language model, alongside a freely available AI-generated fluorescent protein sequence.

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

1 source

⚡

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

⚡

Relationship Map

The relationships surrounding EvolutionaryScale — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far

Jan 2024: Releases ESM3 protein language model open weights→Jun 2024: Launches with record $142M seed round→Jun 2024: EvolutionaryScale launches with record $142M seed, releases ESM3 open weights→Aug 2026: EvolutionaryScale's open-weight strategy builds ecosystem influence but leaves its own mo… (unconfirmed)

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

EvolutionaryScale's open-weight strategy builds ecosystem influence but leaves its own monetization path the least defined of the three protein-design peers

27% confidence

EvolutionaryScale raised the largest seed round on record in synthetic biology ($142 million) and released ESM3's weights openly, but unlike peers Cradle (enterprise software revenue) and Earendil Labs (milestone-based pharma licensing), its own path to monetizing that foundation-model position has not yet been publicly specified.

This is InsightNodes' own interpretive read: releasing ESM3's weights openly is a strong way to become the de facto foundation layer other protein-design tools build on, mirroring open-source strategy plays elsewhere in AI, but it stands in contrast to Cradle's direct enterprise-software revenue and Earendil's milestone-based pharma licensing -- both of which have clearer near-term monetization -- leaving EvolutionaryScale more dependent on downstream commercial products or platform fees that have not yet been publicly detailed.

InsightNodes analysis of EvolutionaryScale's open-weight strategy · Aug 14, 2026

AI Protein Design & Synthetic BiologyEarendil LabsCradle
⚡

EvolutionaryScale's Timeline

A sourced, dated history of EvolutionaryScale's key moments — founding to present.

  1. Jan 2024 · Releases ESM3 protein language model open weights

    EvolutionaryScale released the open weights and code for ESM3, its flagship protein language model, alongside a freely available AI-generated fluorescent protein sequence.

  2. Jun 2024 · Launches with record $142M seed round

    EvolutionaryScale launched with a $142 million seed round, the largest seed financing on record in synthetic biology, founded by former Meta AI researchers.